Skip to main content

Innovation. Clarity. Execution.  I  Portfolio

Portfolio.

Life-changing innovation

The companies in which we have invested since the year 2006 have discovered and developed, fifteen approved medicines and products to the benefit of patients, physicians and our investors.

View and filter our portfolio below

Filter

Acutus
Acutus

Acutus

Cardiac mapping system for AF
Agenus
Agenus

Agenus

Broad immunotherapy platform for cancer
ALETA
ALETA

ALETA

Transformative adoptive cell therapy
Algeta
Algeta

Algeta

Alpha-emitter anticancer agents
Alpha
Alpha

Alpha

Novel oligonucleotide chemistry platform
Amphista
Amphista

Amphista

Targeted Protein Degradation
Aravive
Aravive

Aravive

Therapies targeting survival pathways for cancer
Argá Medtech
Argá Medtech

Argá Medtech

Next Generation Cardiac Ablation
Arrakis
Arrakis

Arrakis

Small molecule modulators of RNA
Artax
Artax

Artax

Novel therapy for autoimmune disease
Aura
Aura

Aura

Novel therapies for ocular cancers
AviadoBio
AviadoBio

AviadoBio

Revolution in gene therapy for neurodegenerative disorders
Avila
Avila

Avila

Covalent small molecule platform
Axonics
Axonics

Axonics

Novel sacral neuromodulation system
Beacon
Beacon

Beacon

Transform lives with pioneering ocular gene therapy
Biocartis
Biocartis

Biocartis

Molecular diagnostics platform
CardiacAssist
CardiacAssist

CardiacAssist

Alpha-emitter anticancer agents
CardiAQ
CardiAQ

CardiAQ

Novel device for mitral valve replacement
Cardiokine
Cardiokine

Cardiokine

Cardio-renal drug development
Cellnovo
Cellnovo

Cellnovo

Micro insulin pump with connectivity
Centessa
Centessa

Centessa

Novel asset-centric pharmaceutical company
CN
CN

CN

Nicotine replacement e-cigarette
Conatus
Conatus

Conatus

Therapeutics for liver disease
Curve
Curve

Curve

Next-gen functional discovery platform
Eloxx
Eloxx

Eloxx

Ribosome Modulating Agents for Rare Disease
Emergent
Emergent

Emergent

Innovative vaccines and therapeutics
Epitopea
Epitopea

Epitopea

Next generation immunotherapies
EUSA
EUSA

EUSA

Trans-Atlantic specialty pharma company
F2G
F2G

F2G

Novel anti-fungal therapy
Highlight
Highlight

Highlight

Bridging the innate to adaptive immune response
Infinity
Infinity

Infinity

Chemical genomic-based drug discovery
Iterum
Iterum

Iterum

Novel oral antibiotic
Kandy
Kandy

Kandy

Therapeutics for Women’s Health
KuDos
KuDos

KuDos

DNA damage repair therapy
Levicept
Levicept

Levicept

Novel pain treatment for osteoarthritis
Micromet
Micromet

Micromet

Bi-specific antibodies
MiroBio
MiroBio

MiroBio

Immune cell regulation
Moximed
Moximed

Moximed

Novel device for treating osteoarthritis of the knee
Nalu
Nalu

Nalu

Novel spinal cord stimulation device
NeRRe
NeRRe

NeRRe

Pipeline of neurokinin antagonists
Orphalan
Orphalan

Orphalan

Rare disease company
Pheno
Pheno

Pheno

Remyelinating therapy development
PIC
PIC

PIC

Targeting oncogene translation
PowderMed
PowderMed

PowderMed

Needle-free vaccine delivery
Proximie
Proximie

Proximie

Best-in-class technology for connected surgical care
Rappta
Rappta

Rappta

Novel PP2A activators to treat cancer
Respivert
Respivert

Respivert

Novel therapies for respiratory disorders
Santarus
Santarus

Santarus

Speciality pharmaceuticals
SEP
SEP

SEP

European pharma focused on urology
Thiakis
Thiakis

Thiakis

Novel hormone treatment for obesity
Tridek-One
Tridek-One

Tridek-One

Novel approach for treatment of vasculitis
UniQure
UniQure

UniQure

Gene therapy for rare disease
Ventus
Ventus

Ventus

Innovative smoking cessation products

About

Leading Venture Investors
Learn More

Exit History

View Our Exit History
Learn More